Nuclear ubiquitination permits Hippo-YAP signal for liver development and tumorigenesis
- PMID: 40379800
- DOI: 10.1038/s41589-025-01901-8
Nuclear ubiquitination permits Hippo-YAP signal for liver development and tumorigenesis
Erratum in
-
Author Correction: Nuclear ubiquitination permits Hippo-YAP signal for liver development and tumorigenesis.Nat Chem Biol. 2025 Jun 10. doi: 10.1038/s41589-025-01958-5. Online ahead of print. Nat Chem Biol. 2025. PMID: 40494977 No abstract available.
Abstract
Hippo-YAP signaling is crucial to organ development and tumorigenesis. VGLL4, which occupies TEAD to prevent YAP binding, is the main transcriptional repressor of Hippo-YAP activity. Here we identified the nuclear E3 ligase ubiquitin protein ligase E3 component n-recognin 5 (UBR5) poly-ubiquitinated VGLL4 at Lys61 for its degradation, which permits Hippo-YAP signaling for the development of the liver biliary system in mice and multiple cancers in humans. In mouse liver development, Ubr5 and Vgll4 exhibited reciprocal expression patterns spatiotemporally. Ubr5 deletion impaired cholangiocyte development and hepatocyte reprogramming, which could be efficiently rescued by restoring Hippo-YAP through ablating Vgll4. We also found that the UBR5-VGLL4-YAP axis is associated with the progression of human pan-cancers. Targeting nuclear E3 ligases in multiple types of patient-derived tumor organoids suppressed their expansion. Our identification of UBR5 as the bona fide E3 ligase of VGLL4 offers a molecular framework of nuclear Hippo-YAP regulation and suggests nuclear ubiquitination as a potential therapeutic target for YAP-dependent malignancies.
© 2025. The Author(s), under exclusive licence to Springer Nature America, Inc.
Conflict of interest statement
Competing interests: The authors declared no conflict of interest.
Similar articles
-
YAP-VGLL4 antagonism defines the major physiological function of the Hippo signaling effector YAP.Genes Dev. 2022 Nov-Dec 1;36(21-24):1119-1128. doi: 10.1101/gad.350127.122. Epub 2022 Dec 15. Genes Dev. 2022. PMID: 36522128 Free PMC article.
-
Regulation of Hippo/YAP signaling and Esophageal Squamous Carcinoma progression by an E3 ubiquitin ligase PARK2.Theranostics. 2020 Jul 25;10(21):9443-9457. doi: 10.7150/thno.46078. eCollection 2020. Theranostics. 2020. PMID: 32863938 Free PMC article.
-
SKP2 and OTUD1 govern non-proteolytic ubiquitination of YAP that promotes YAP nuclear localization and activity.Cell Stress. 2018 Aug 14;2(9):233-235. doi: 10.15698/cst2018.09.153. Cell Stress. 2018. PMID: 31225491 Free PMC article.
-
VGLL4 is a transcriptional cofactor acting as a novel tumor suppressor via interacting with TEADs.Am J Cancer Res. 2018 Jun 1;8(6):932-943. eCollection 2018. Am J Cancer Res. 2018. PMID: 30034932 Free PMC article. Review.
-
Regulation of the Hippo signaling pathway by ubiquitin modification.BMB Rep. 2018 Mar;51(3):143-150. doi: 10.5483/bmbrep.2018.51.3.017. BMB Rep. 2018. PMID: 29366444 Free PMC article. Review.
Cited by
-
Enabling RNA-compatible synthetic receptors through RNA editing.Nat Rev Mol Cell Biol. 2025 Aug;26(8):581. doi: 10.1038/s41580-025-00863-y. Nat Rev Mol Cell Biol. 2025. PMID: 40399645 No abstract available.
References
Grants and funding
LinkOut - more resources
Full Text Sources